KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
13 févr. 2024 07h00 HE | Krystal Biotech, Inc.
• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
08 févr. 2024 07h00 HE | Krystal Biotech, Inc.
• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional applications of Krystal’s HSV-1 platform to treat ocular diseases • Repeat...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
01 févr. 2024 07h00 HE | Krystal Biotech, Inc.
PITTSBURGH, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
04 janv. 2024 07h00 HE | Krystal Biotech, Inc.
PITTSBURGH, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
19 déc. 2023 07h00 HE | Krystal Biotech, Inc.
PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
27 nov. 2023 07h00 HE | Krystal Biotech, Inc.
If approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for the first timeVYJUVEK received Orphan Drug Designation and PRIME...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
09 nov. 2023 07h00 HE | Krystal Biotech, Inc.
PITTSBURGH, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
06 nov. 2023 07h00 HE | Krystal Biotech, Inc.
•   284 VYJUVEK Patient Start Forms and $8.6 million in VYJUVEK U.S. net product revenue as of the end of the third quarter •   Cohort 1 completed in Phase 1 clinical trial of KB407 for the treatment...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023
30 oct. 2023 07h00 HE | Krystal Biotech, Inc.
PITTSBURGH, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
KRYS logo no_background.png
Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
28 sept. 2023 07h00 HE | Krystal Biotech, Inc.
PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...